IQVIA™ Real-World Insights Bibliography

Reduction in the Utilization of Prednisone or Methotrexate in Canadian Claims Data Following Initiation of Etanercept in Pediatric Patients with Juvenile Idiopathic Arthritis
Author(s): Majed M M Khraishi1, Brad Millson2, John Woolcott3, Lisa Marshall4 and Heather Jones4
Affiliations(s): 1Memorial University of Newfoundland, St John's, NF, Canada, 2IQVIA, Kanata, ON, Canada, 3Global Outcomes & Evidence, Pfizer, Collegeville, PA, 4Pfizer, Collegeville, PA
Publication(s):  Annals of the Rheumatic Diseases 2018;77:494.
Document Type(s): Article,
Countries: Canada,
Click here for the abstract
C:
Y:
Pediatrics, Rheumatology,
2019
  L:
A:
English
Longitudinal study, Retrospective database analysis,
  Add to report
 
 
Real-world utilization of methotrexate or prednisone co-therapy with etanercept among Canadian patients with rheumatoid arthritis: a retrospective cohort study
Author(s): Majed Khraishi, Jelena Ivanovic, Yvonne Zhang, Brad Millson, Marie-Josee Brabant, John Woolcott, Heather Jones & Cinzia Curiale
Affiliations(s): 
Publication(s):  Journal of Current Medical Research and Opinion, Accepted author version posted online: 25 Jun 2019, Published online: 10 Jul 2019
Document Type(s): Article,
Countries: Canada,
Click here for the abstract
C:
Y:
Rheumatology,
2019
  L:
A:
English
Retrospective cohort analysis,
  Add to report
 
 
Two-year adherence and costs for biologic therapy for rheumatoid arthritis
Author(s): Stolshek BS, Wade S, Mutebi A, De AP, Wade RL, Yeaw J
Affiliations(s): Amgen, IQVIA
Publication(s):  Am J Manag Care
Document Type(s): Article,
Countries: USA,
Click here for the abstract
C:
Y:
Rheumatology,
2018
  L:
A:
English
Cost analysis, Retrospective cohort analysis,
  Add to report
 
 
Assessing Treatment Tolerability for Rheumatoid Arthritis. Validation and Practical Applications of the ?TOL-AR-18 Questionnaire
Author(s): Corominas H, Espadaler L, Gómez A, Ros I, Urruticoechea A, Sarmiento M, Sanmartí R
Affiliations(s): Corominas H.: Rheumatology and Autoimmune diseases Division, Hospital Universitari de Sant Pau & Hospital Dos de Maig, Barcelona, Spain Sarmiento M: Real-World Evidence Solutions, IMS Health, Spain
Publication(s):  Reumatología Clínica 2018; Sep 5. [Epub ahead of print]
Document Type(s): Article,
Countries: Spain,
Click here for the abstract
C:
Y:
Health status & patient reported outcomes, Rheumatology,
2018
  L:
A:
English
Clinical setting: hospital, Observational study,
  Add to report
 
 
Canadian Study of Adherence Outcomes in HUMIRA® (Adalimumab) Patients – Three-Year Results from the COMPANION Study in Rheumatology Patients
Author(s): Bessette L1, Millson B2, Sung M2, Gaetano T3, Latour M3, Laliberté MC3
Affiliations(s): 1 Department of Medicine, Laval University, Quebec City, Quebec, Canada 2 IMS Brogan, Kirkland, Quebec, Canada; 3AbbVie Corporation, St. Laurent, Quebec, Canada
Publication(s):  Canadian Rheumatology Association 2017 Scientific Meeting, February 8-11, Ottawa, Canada
Document Type(s): Poster,
Countries: Canada,
Click here for the abstract
C:
Y:
Rheumatology,
2017
  L:
A:
English
Database Study,
  Add to report
 
 
Regional policies impact on biosimilar adoption for autoimmune diseases in Italy
Author(s): Tucci C1, Rova A1, Mantuano M1, Tettamanti A1
Affiliations(s): QuintilesIMS, Milan, Italy
Publication(s):  ISPOR 20th Annual European Congress, 4-8 November 2017, Glasgow, Scotland
Document Type(s): Poster,
Countries: Italy,
C:
Y:
Dermatology, Gastrointestinal disorders, Health policy, Rheumatology,
2017
  L:
A:
English
Literature Review,
  Add to report
 
 
Market share and switching dynamics between Etanercept and its biosimilar product in Sweden and Germany: a real-world preliminary analysis.
Author(s): Alten R1, Neregård P2, Jones HE3, Meng T4, Curiale C5, Singh E6, Lucchese L7, Gossen N8, Bergman GJ9, Miglio C7
Affiliations(s): 1 Shlosspark-Klinik Teaching Hospital of the Charité, Berlin, Germany 2 Pfizer, Sollentuna, Sweden 3 Pfizer inc., Collegeville, PA, USA 4 Pfizer Pharma GmbH, Berlin, Germany 5 Pfizer, Rome, Italy 6 Pfizer Inc., Collegeville, PA, USA 7 QuintilesIMS, London, UK 8 QuintilesIMS, Frankfurt, Germany 9 QuintilesIMS, Solna, Sweden
Publication(s):  ISPOR 20th Annual European Congress
Document Type(s): 
Countries: Germany, Sweden,
Click here for the abstract
C:
Y:
Immunology and Vaccination, Patient Registries & Real-World Study Methods, Rheumatology,
2017
  L:
A:
English
Retrospective database analysis,
  Add to report
 
 
Depression risk in patients with rheumatoid arthritis in the United Kingdom
Author(s): Jacob L,Rockel T, Kostev K
Affiliations(s): 
Publication(s):  Rheumatol Ther. 2017 Mar 20. doi: 10.1007/s40744-017-0058-2. [Epub ahead of print]
Document Type(s): Article,
Countries: UK,
C:
Y:
Mental health, Rheumatology,
2017
  L:
A:
English
  Add to report
 
 
COMMONALITIES AND DIFFERENCES IN DATA COLLECTION ACROSS EUROPEAN SPONDYLOARTHRITIS REGISTRIES
Author(s): M. L. Hetland* 1, M. Østergaard1, J. Askling2, C. Gabay3, D. Nordstrom4, O. FitzGerald5, M. Hernández Miguel6, M. Santos7 , Z. Rotar8, H. Mann9, F. Iannone10, M. J. Nissen3, E. Hauge1, J. Gomez-Reino11, F. Díaz-González12, M. Tomsic8, K. Pavelka9, F. O'Shea5, C. Sullivan5, M. van de Sande13, I. E. van der Horst-Bruinsma13, G. J. Macfarlane14, G. T. Jones14, B. Gudbjørnsson15, T. K. Kvien16 on behalf of EuroSpA Study Group
Affiliations(s): 1DANBIO, Glostrup, Denmark, 2ARTIS, Stockholm, Sweden, 3SCQM, Geneva, Switzerland, 4ROB-FIN, Helsinki, Finland, 5ASRI, Dublin, Ireland, 6BIOBADASER, Barcelona, Spain, 7reuma.pt, Almada, Portugal, 8biorx.si, Ljubljana, Slovenia, 9ATTRA, Prague, Czech Republic, 10GISEA, Bari, Italy, 11BIOBADASER, Santiago, 12BIOBADASER, Santa Cruz de Tenerife, Spain, 13ARC, Amsterdam, Netherlands, 14BSRBR-AS, Aberdeen, United Kingdom, 15ICEBIO, Reykjavik, Iceland, 16NORDMARD, Oslo, Norway
Publication(s):  EULAR, Madrid, 2017
Document Type(s): Abstract,
Countries: Czech, Denmark, Finland, Ireland, Italy, Norway, Slovenia, Spain, Sweden, Switzerland,
Click here for the abstract
C:
Y:
Rheumatology,
2017
  L:
A:
English
Epidemiological study,
  Add to report
 
 
Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Author(s): Lyu R1, Govoni M2, Ding Q1, Black CM3, Kachroo S4, Fan T1, Ogbonnaya A5, Donga P5, Hill J5, Makin C5.
Affiliations(s): 1Merck Co., Inc, Whitehouse Station, NJ, USA. 2MSD Italy, Rome, Italy. 3Merck Co., Inc, 126 E. Lincoln Avenue, Mail code: RY32-211, Rahway, NJ, 07065, USA. 4Merck Co., Inc, 126 E. Lincoln Avenue, Mail code: RY32-211, Rahway, NJ, 07065, USA. sumesh.kachroo@merck.com. 5IMS Health, Alexandria, VA, USA.
Publication(s):  Rheumatol Int. 2016 Jan;36(1):143-53.
Document Type(s): Article,
Countries: Germany,
Click here for the abstract
C:
Y:
Rheumatology,
2016
  L:
A:
English
Retrospective database analysis,
  Add to report
 
 
 1 of 11 Next Page Last Page